Targepeutics raised $0.2 million to develop molecularly targeted therapies for rare cancers and other diseases, minimizing harm to healthy cells while treating difficult-to-treat conditions.
Targepeutics raised $0.2 million to develop molecularly targeted therapies for rare cancers and other diseases, minimizing harm to healthy cells while treating difficult-to-treat conditions.